Valproic acid as a monotherapy in drug-resistant methyl-CpG-binding protein 2 gene (MECP2) duplication-related epilepsy
Open Access
- 9 October 2018
- journal article
- case report
- Published by Elsevier in Epilepsy & Behavior Case Reports
- Vol. 10, 133-136
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Lamotrigine versus valproic acid monotherapy for generalised epilepsy: A meta-analysis of comparative studiesSeizure: European Journal of Epilepsy, 2017
- Anticonvulsant drugs for generalized tonic-clonic epilepsyExpert Opinion on Pharmacotherapy, 2017
- Late onset epileptic spasms is frequent in MECP2 gene duplication: Electroclinical features and long-term follow-up of 8 epilepsy patientsEuropean Journal of Paediatric Neurology, 2014
- Structural variation in Xq28: MECP2 duplications in 1% of patients with unexplained XLMR and in 2% of male patients with severe encephalopathyEuropean Journal of Human Genetics, 2008
- Recurrent Infections, Hypotonia, and Mental Retardation Caused by Duplication of MECP2 and Adjacent Region in Xq28Pediatrics, 2006
- Duplication of the MECP2 Region Is a Frequent Cause of Severe Mental Retardation and Progressive Neurological Symptoms in MalesThe American Journal of Human Genetics, 2005
- Submicroscopic duplication in Xq28 causes increased expression of the MECP2 gene in a boy with severe mental retardation and features of Rett syndromeJournal of Medical Genetics, 2005
- Valproic-Acid-Induced Thrombocytopenia and Hepatotoxicity: Discontinuation of Treatment?Pharmacology, 2004
- Pharmacology of valproate.2003
- Lamotrigine substitution study: evidence for synergism with sodium valproate?Epilepsy Research, 1997